Drug-induced nutrient depletion
How common drugs — statins, metformin, proton pump inhibitors, and diuretics — deplete essential vitamins and minerals, the clinical consequences, and evidence-based monitoring and supplementation strategies.
Key drug–nutrient depletion interactions
| Drug / Drug class | Nutrient(s) depleted | Mechanism | Clinical consequence | Monitoring / action |
|---|---|---|---|---|
| Statins | Coenzyme Q10 (CoQ10/ubiquinone) | Mevalonate pathway inhibition reduces CoQ10 synthesis | Myalgia, fatigue (evidence debated) | CoQ10 100–300 mg/day if SAMS present |
| Metformin | Vitamin B12 | Impairs calcium-dependent ileal receptor (cubilin) | Peripheral neuropathy, anaemia | Serum B12 annually; supplement if <300 pmol/L |
| PPIs | Magnesium, Vitamin B12, Calcium, Iron | Gastric acid suppression reduces mineral solubility and B12 pepsin-release | Hypomagnesaemia (arrhythmia, seizure), B12 deficiency | Serum Mg annually; use calcium citrate; B12 if symptomatic |
| Loop diuretics | Potassium, Magnesium, Thiamine, Zinc, Calcium | Increased renal wasting at loop of Henle | Arrhythmia (K/Mg); wet beriberi in HF (thiamine) | UEC every 3–6 months; thiamine 100 mg/day in HF |
| Thiazide diuretics | Potassium, Magnesium | DCT Na-Cl cotransporter blockade reduces K reabsorption | Hypokalaemia, hypomagnesaemia | UEC monitoring; consider K-sparing agent |
| Oral contraceptives | Folate, Vitamin B6, B12 | Altered metabolism and urinary folate excretion | Neural tube defect risk at conception; peripheral neuropathy | Folate 400–800 mcg/day; B6 if deficient |
| Corticosteroids (long-term) | Calcium, Vitamin D, Potassium | Reduces intestinal Ca absorption; increases renal Ca wasting | Osteoporosis, adrenal-related hypokalaemia | Ca 1000–1500 mg/day + Vit D 800–1000 IU/day; bisphosphonate if bone loss |
| Isoniazid (INH) | Vitamin B6 (pyridoxine) | INH is a structural analogue of B6; inhibits pyridoxal kinase | Peripheral neuropathy (INH neuropathy) | Pyridoxine 25–50 mg/day co-prescribed universally |
Depletion mechanisms in depth
Absorption impairment
PPIs and H2 blockers reduce gastric acid, impairing: (1) ionisation of mineral salts (Fe, Ca carbonate, Mg); (2) pepsin-mediated cleavage of protein-bound B12 from food; (3) vitamin C-dependent ferric reduction. Metformin impairs active transport at the ileal cubilin receptor — calcium-dependent and reversible with calcium supplementation. Cholestyramine binds fat-soluble vitamins (A, D, E, K) and some water-soluble vitamins in the gut lumen.
Increased renal excretion
Loop diuretics block the Na-K-2Cl cotransporter in the thick ascending limb — markedly increasing urinary loss of Na, K, Mg, Ca, Zn, and thiamine. Thiazides block the DCT Na-Cl cotransporter — K and Mg wasted, but Ca is paradoxically reabsorbed (clinically useful in hypercalciuria/nephrolithiasis). ACE inhibitors and ARBs reduce aldosterone → potassium retention (hyperkalaemia risk, not depletion).
Biosynthesis inhibition
Statins inhibit HMG-CoA reductase, reducing production of mevalonate — a precursor shared by cholesterol, CoQ10 (ubiquinone), dolichol, and haem A. This depletes endogenous CoQ10, an essential cofactor in the mitochondrial electron transport chain. Isoniazid inhibits pyridoxal kinase, blocking conversion of pyridoxine to pyridoxal-5'-phosphate (active B6 form) — mandatory B6 co-prescription prevents INH neuropathy.
Metabolic interference
Oral contraceptives containing oestrogen alter folate metabolism via induction of folate-catabolising enzymes and increase urinary folate excretion. B6 deficiency risk is linked to oestrogen-mediated competition in tryptophan metabolism pathways. Trimethoprim and methotrexate inhibit dihydrofolate reductase (DHFR) — preventing activation of folate to tetrahydrofolate, causing functional folate deficiency despite normal serum folate levels.
Metformin vitamin B12 monitoring: official guidance
Metformin vitamin B12 monitoring official guidance has evolved significantly as evidence of clinically important B12 depletion has accumulated. The following organisations now recommend periodic B12 monitoring in metformin-treated patients:
- ADA Standards of Care (2024): The American Diabetes Association recommends periodic monitoring of vitamin B12 levels in patients on long-term metformin therapy, particularly those with anaemia or peripheral neuropathy. The ADA notes that metformin can cause vitamin B12 deficiency and that B12 levels should be measured if deficiency is suspected.
- FDA metformin labelling: The updated FDA metformin label (DailyMed) ↗ now includes a warning that metformin may reduce vitamin B12 levels and recommends measuring B12 periodically in patients at risk of deficiency.
- NICE (UK): The National Institute for Health and Care Excellence recommends annual monitoring of B12 in patients on metformin if they develop symptoms of peripheral neuropathy or macrocytic anaemia.
- Endocrine Society: Recommends B12 level at baseline, then annually in long-term metformin users, with supplementation if serum B12 falls below 300 pmol/L (or 220 pg/mL).
The clinical significance of this guidance is underscored by the fact that metformin-induced B12 deficiency neuropathy is clinically indistinguishable from diabetic peripheral neuropathy (DPN), leading to potential misattribution and under-treatment. Screening with serum B12 (or methylmalonic acid for borderline levels) at baseline and annually enables early detection and treatment with oral cyanocobalamin 1,000–2,000 mcg/day. See the NCBI metformin B12 depletion review ↗ and our diabetes medications guide for the full pharmacology of metformin.